Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy, Immunotherapy.

Christie Hospital NHS Trust, Manchester, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:3City/State/Province:Manchester
Treatments:Biologic therapy, ImmunotherapyHospital:Christie Hospital NHS Trust
Drugs:Journal:Link
Date:Feb 2007

Description:

Patients: This phase II study involved 43 patients with renal cell carcinoma. Of these patients, most (35) were men.

Treatment: All patients were treated with a 5T4 oncofoetal antigen tumour-targeted superantigen, ABR-214936. This therapy is a superantigen combined with an antibody against a molecule found on tumors. This superantigen stimulates the immune system and helps the antibody work.

Toxicity: Grade 3 hypotension was reported. The most common adverse events were pyrexia, rigour, lethargy/fatigue, nausea/vomiting, hypotension and hypertension.

Results: The median overall survival was 19.7 months. At the time this study was reported, 13 patients were alive.

Support: This study was supported by Active Biotech AB, the company that developed this therapeutic, which is also known as ANYARA.

Correspondence: Dr. DM Shaw



Back